{
    "nct_id": "NCT04191499",
    "official_title": "A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer",
    "inclusion_criteria": "Inclusion Criteria\n\n* Confirmed diagnosis of HR+/HER2- breast cancer\n* Metastatic or locally advanced disease not amenable to curative therapy\n* Progression of disease during adjuvant endocrine treatment or within 12 months of completing adjuvant endocrine therapy with an aromatase inhibitor or tamoxifen\n* Receiving LHRH agonist therapy for at least 2 weeks prior to Day 1 of Cycle 1 if pre/peri-menopausal\n* Confirmation of biomarker eligibility (detection of specified mutation(s) of PIK3CA via specified test)\n* Consent to provide fresh or archival tumor tissue specimen\n* Measurable disease per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1); evaluable \"bone-only\" disease is not eligible; \"bone-only\" disease with at least one measurable, soft-tissue component, even if considered disease that is limited to bone but has lytic or mixed lytic/blastic lesions and at least one measurable soft-tissue component per RECIST v1.1 may be eligible\n* Eastern Cooperative Oncology Group Performance Status of 0 or 1\n* Life expectancy of > 6 months\n* Adequate hematologic and organ function within 14 days prior to initiation of study treatment\n\nExclusion Criteria\n\n* Metaplastic breast cancer\n* Any history of leptomeningeal disease or carcinomatous meningitis\n* Any prior systemic therapy for metastatic breast cancer\n* Prior treatment with fulvestrant or any selective estrogen-receptor degrader, with the exception of participants that have received fulvestrant or any selective estrogen-receptor degrader as part of neoadjuvant therapy only and with treatment duration of no longer than 6 months\n* Prior treatment with any PI3K, AKT, or mTOR inhibitor, or any agent whose mechanism of action is to inhibit the PI3K-AKT-mTOR pathway\n* Type 2 diabetes requiring ongoing systemic treatment at the time of study entry; or any history of Type 1 diabetes\n* Known and untreated, or active CNS metastases. Patients with a history of treated CNS metastases may be eligible\n* Active inflammatory or infectious conditions in either eye, or any eye conditions expected to require surgery during the study treatment period\n* Symptomatic active lung disease, or requiring daily supplemental oxygen\n* History of inflammatory bowel disease or active bowel inflammation\n* Anti-cancer therapy within 2 weeks before study entry\n* Investigational drug(s) within 4 weeks before randomization\n* Prior radiotherapy to >= 25% of bone marrow, or hematopoietic stem cell or bone marrow transplantation\n* Chronic corticosteroid therapy or immunosuppressants\n* Pregnant, lactating, or breastfeeding, or intending to become pregnant during the study or within 2 weeks after the final dose of study treatment\n* Major surgical procedure, or significant traumatic injury, within 28 days prior to Day 1 of Cycle 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}